Spanish scientists identify a new ancestral enzyme that facilitates DNA repair

November 20, 2013

Every day, the human body produces new cells to regenerate tissues and repair those that have suffered injury. Each time this happens, the cells make copies of their DNA that they will pass on to the resulting daughter cells. This process of copying the DNA, also called replication, is very delicate, given that it can generate severe alterations in the DNA that are associated with malignant transformation or ageing.

Researchers from the Spanish National Cancer Research Centre (CNIO), led by Juan Méndez, head of the DNA Replication Group, together with Luis Blanco, from the Severo Ochoa Molecular Biology Centre (CBM-CSIC), have discovered how a new human enzyme, the protein PrimPol, is capable of recognising DNA lesions and facilitate their repair during the DNA copying process, thus avoiding irreversible and lethal damage to the cells and, therefore, to the organism.

The results are published in the online edition of the journal Nature Structural and Molecular Biology. This study represents the continuation of a prior study, published recently by the same researchers in the journal Molecular Cell, in which they described the existence and biochemical properties of the PrimPol enzyme.

The DNA that resides in the nucleus of cells is the carrier of the genes, the instruction manuals that dictate how the cell works. "DNA structure is very stable, except during replication which normally takes approximately eight hours in human cells; during that period it becomes more fragile and can break", says Méndez. These eight hours are therefore critical for cells: they have to ensure the fidelity of copying DNA, and if errors are found or the DNA is damaged, they have to repair them as efficiently as possible.

AVOIDING COLLAPSE

DNA polymerases are the enzymes responsible for synthesising new DNA. "When a DNA polymerase finds an obstacle in the DNA [a chemical alteration introduced by solar ultraviolet radiation, for example], the copy is interrupted and the process stops until the error is repaired. This interruption can cause breaks in the DNA, translocations of fragments from some chromosomes to others, and even cause cell death or malignant transformation", says Méndez.

The research carried out by CNIO and CSIC demonstrates that the PrimPol enzyme prevents the copying process from being interrupted when there is damage: it recognises lesions and skips over them, and they are repaired when the copy is finished.

In evolutionary terms, PrimPol is a very old enzyme, and similar proteins have been found in archaebacteria, one of the first life forms that inhabited the Earth. "Millions of years ago, life conditions were more difficult [high salinity, extreme temperatures, etc.], so PrimPol has probably adapted to synthesising DNA in these conditions that encourage damage", says Méndez, adding that: "in exchange, these primitive DNA polymerases are less exact than the more evolved copying systems and can introduce mutations".

The scientists anticipate that this increase in mutations could have played a key role in the evolution of genomes, as well as having an impact on the ageing of cells and the development of cancer. Having identified and characterised this new protein in human beings, the researchers tell us that they are already studying its role in disease development.
-end-
Reference article:

Repriming of DNA synthesis at stalled replication forks by human PrimPol. Silvana Mourón, Sara Rodriguez-Acebes, María I. Martínez-Jiménez, Sara García-Gómez, Sandra Chocrón, Luis Blanco, Juan Méndez. Nature Structural & Molecular Biology (2013). DOI: 10.1038/nsmb.2719

Centro Nacional de Investigaciones Oncológicas (CNIO)

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.